

Clearbridge Expands Primary Healthcare Presence in Hong Kong with Larger Clinic at Causeway Bay

- *Size of new clinic to increase to 1,500 square feet from the current 800 square feet that served an estimated 350 patients per month, of which the majority are medical tourists from China*
- *New clinic to accommodate more visiting physicians and specialists and provide a wider range of medical and health screening services*
- *Collaboration with more insurance companies and healthcare partners to serve more domestic patients and medical tourists*
- *Adherence to Singapore's high standards enhances the clinic's branding and upholds public confidence*

SINGAPORE, 3 June 2019 – Integrated healthcare company, **Clearbridge Health Limited** (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (“明策集团”), is pleased to announce that it is expanding its primary healthcare presence in Hong Kong with a new and larger clinic in Causeway Bay to serve more domestic patients and medical tourists.

Previously, the Group's clinic in Hong Kong was approximately 800 square feet and served an estimated 350 patients per month, of which the majority are medical tourists from China.

With a view to enhancing the patient experience, the size of the new clinic at approximately 1,500 square feet is almost twice the size of the previous clinic. The new clinic can accommodate more visiting physicians and specialists (such as obstetrician, gynaecologist and gastroenterology) and provide a wider range of medical and health screening services to meet the growing medical needs of this market segment.

In addition, there is a dedicated space within the new clinic to hold educational health talks and events for medical tourist agents and patients to have better understanding and knowledge on various third party world-class medical services and solutions offered by the Group in Asia.

As part of Clearbridge's precision medicine platform, the clinic adheres to Singapore's high standards that enhances the clinic's branding and upholds public confidence in its medical services.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said, “Hong Kong's proximity to China has been a boost for medical tourism and with our collaborations with insurance companies and healthcare partners, we are seeing increasing demand for our primary healthcare services from this market segment.



Supporting the growth of Clearbridge’s precision medicine platform in Asia, our new clinic in Hong Kong enhances our capabilities to serve more patients and create new cross-selling opportunities of the various third party world-class medical services and solutions offered by the Group.”

– END –

Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About Clearbridge Health Limited

(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises healthcare systems, medical clinics/centres and strategic equity investments in medical technology companies.

Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. It is executing the above strategies by way of primary healthcare and healthcare systems that reside in nexus of high demand.

For more information, please visit us at www.clearbridgehealth.com.

This press release has been prepared by the Company and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.